MarketBeat
11 Jul 2026, 17:02 UTC · 2h ago
Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
11 Jul 2026, 17:02 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Retrospective application of the revised stage two design to 25 patients showed a 53.2% treatment difference for week four IGA success and p-values below 0.05 for both IGA and EASI-75 endpoints. — Strong positive efficacy signals and statistical significance in a refined patient subgroup increase the probability of clinical success.
+0.60GX-03 has shown a favorable safety profile with no treatment-related serious adverse events or new safety signals reported to date. — Clean safety data reduces the risk of trial termination or regulatory hurdles, though safety is a baseline requirement rather than a primary driver of upside.
+0.30The company expects the stage two data readout in the fourth quarter of 2026, with a potential phase III trial initiation in mid-2027. — The extended timeline to a 2026 readout delays the potential for commercialization and creates a long period of capital risk.
-0.20Continue reading
6 related stories
Top 3 movers · tap to explore
Turn Therapeutics is expanding the trial focus to include patients with lower EASI scores (1.1 to 7) after interim analysis showed meaningful results in that subgroup. — Expanding the addressable patient population potentially increases the drug's future market size if these results hold.
+0.20The company is enriching the stage two population by requiring a baseline pruritus (itch) score of at least seven to increase the probability of success. — Using data-driven enrichment strategies optimizes the trial for a positive outcome, though it narrows the initial target population.
+0.10Which stocks this story touches
The company reported positive interim analysis data and a favorable safety profile for its GX-03 phase II program.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
The Motley Fool
4h ago
